Octagon Capital Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Octagon Capital Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	-$105K	–	58
2023 Q4	$105K	Buy	+100,000	New	+$305K	0.02%	33
2023 Q2	–	Sell	-577,000	Closed	-$4.67M	–	42
2023 Q1	$4.67M	Buy	+577,000	New	+$7.32M	0.67%	26
2021 Q1	–	Sell	-350,000	Closed	-$2.27M	–	29
2020 Q4	$2.27M	Buy	+350,000	New	+$1.48M	0.79%	29

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Octagon Capital Advisors's ACRS Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 100,000 shares — an estimated $105K sold.

Octagon Capital Advisors first reported a position in ACRS in Q4 2020 and held it in 3 quarters. The position peaked at $4.67M in Q1 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

Octagon Capital Advisors reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
Octagon Capital Advisors sold 100,000 Aclaris Therapeutics shares in Q1 2024, an estimated $105K.
Octagon Capital Advisors first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 3 quarters.
Octagon Capital Advisors's Aclaris Therapeutics position peaked at $4.67M in Q1 2023.
98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.